Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 2
2011 1
2012 4
2013 8
2014 11
2015 9
2016 14
2017 16
2018 17
2019 30
2020 33
2021 28
2022 43
2023 51
2024 14

Text availability

Article attribute

Article type

Publication date

Search Results

216 results

Results by year

Filters applied: . Clear all
Page 1
Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapy.
Chen ST, Semenov YR, Alloo A, Bach DQ, Betof Warner A, Bougrine A, Burton L, Cappelli LC, Castells M, Cohen J, Dewan AK, Fadden R, Guggina L, Hegde A, Huang V, Johnson DB, Kaffenberger B, Kroshinsky D, Kwatra S, Kwong B, Lacouture ME, Larocca C, Leventhal J, Markova A, McDunn J, Mooradian MJ, Naidoo J, Choi J, Nambudiri V, Nelson CA, Patel AB, Pimkina J, Rine J, Rubin KM, Sauder M, Shaigany S, Shariff A, Sullivan RJ, Zubiri L, Reynolds KL, LeBoeuf NR. Chen ST, et al. Among authors: kaffenberger b. J Immunother Cancer. 2024 Apr 10;12(4):e007675. doi: 10.1136/jitc-2023-007675. J Immunother Cancer. 2024. PMID: 38599660 Free PMC article.
Hemorrhagic Crescent Sign in Pseudocellulitis.
Hamp A, Huttinger ZM, Kaffenberger BH. Hamp A, et al. Among authors: kaffenberger bh. Cutis. 2024 Feb;113(2):E28-E29. doi: 10.12788/cutis.0977. Cutis. 2024. PMID: 38593096 No abstract available.
No impact of immunomodulatory treatments on SARS-CoV-2 (COVID-19) vaccine outcomes: A cross-sectional analysis of biologic and small molecule inhibitors used for psoriasis and hidradenitis suppurativa patients from the Epic Cosmos database.
Lee BR, Brostek AR, Kaffenberger BH. Lee BR, et al. Among authors: kaffenberger bh. J Am Acad Dermatol. 2024 Mar 13:S0190-9622(24)00485-7. doi: 10.1016/j.jaad.2024.03.004. Online ahead of print. J Am Acad Dermatol. 2024. PMID: 38490372 No abstract available.
The United States dermatology inpatient workforce between 2013 and 2019: a Medicare analysis reveals contraction of the workforce and vast access deserts-a cross-sectional analysis.
Hydol-Smith JA, Gallardo MA, Korman A, Madigan L, Shearer S, Nelson C, Fisher K, Hoffman K, Dominguez A, Kaffenberger BH. Hydol-Smith JA, et al. Among authors: kaffenberger bh. Arch Dermatol Res. 2024 Mar 14;316(4):103. doi: 10.1007/s00403-024-02845-0. Arch Dermatol Res. 2024. PMID: 38485858 Free PMC article.
Ectatic Vessels on the Chest.
Rose L, Minta A, Chung C, Kaffenberger BH. Rose L, et al. Among authors: kaffenberger bh. Cutis. 2024 Jan;113(1):E15-E16. doi: 10.12788/cutis.0937. Cutis. 2024. PMID: 38478943 No abstract available.
Perioperative management and clinical outcomes of peristomal pyoderma gangrenosum.
Becker SL, Rios-Duarte JA, Morrison GM, Xia E, Mostaghimi A, Himed S, Kaffenberger BH, Zhang D, Shields BE, Cogen AL, Ortega-Loayza AG. Becker SL, et al. Among authors: kaffenberger bh. Arch Dermatol Res. 2024 Mar 6;316(4):98. doi: 10.1007/s00403-024-02826-3. Arch Dermatol Res. 2024. PMID: 38446235 Review.
Quality of Life with Neutrophilic Dermatoses.
Gray AN, Mital R, Minta A, Waters M, Almhana F, Hydol-Smith J, Kaffenberger BH. Gray AN, et al. Among authors: kaffenberger bh. Dermatol Clin. 2024 Apr;42(2):329-338. doi: 10.1016/j.det.2023.08.011. Epub 2023 Sep 14. Dermatol Clin. 2024. PMID: 38423691 Review.
Managing hyperglycemia and rash associated with alpelisib: expert consensus recommendations using the Delphi technique.
Gallagher EJ, Moore H, Lacouture ME, Dent SF, Farooki A, Goncalves MD, Isaacs C, Johnston A, Juric D, Quandt Z, Spring L, Berman B, Decker M, Hortobagyi GN, Kaffenberger BH, Kwong BY, Pluard T, Rao R, Schwartzberg L, Broder MS. Gallagher EJ, et al. Among authors: kaffenberger bh. NPJ Breast Cancer. 2024 Jan 31;10(1):12. doi: 10.1038/s41523-024-00613-x. NPJ Breast Cancer. 2024. PMID: 38297009 Free PMC article.
Eligibility Criteria for Active Ulcerative Pyoderma Gangrenosum in Clinical Trials: A Delphi Consensus on Behalf of the UPGRADE (Understanding Pyoderma Gangrenosum: Review and Assessment of Disease Effects) Group.
Kamal K, Xia E, Li SJ, Alavi A, Cogen AL, Firooz A, Marzano AV, Kaffenberger BH, Sibbald C, Fernandez AP, Callen JP, Dissemond J, Gontijo JRV, Shams K, Gerbens LA, French LE, Gould LJ, Bissonnette R, Shaigany S, Tolkachjov S, Yamamoto T, Wei-Ting Huang W, Ortega-Loayza AG, Mostaghimi A. Kamal K, et al. Among authors: kaffenberger bh. J Invest Dermatol. 2023 Dec 16:S0022-202X(23)03193-7. doi: 10.1016/j.jid.2023.12.006. Online ahead of print. J Invest Dermatol. 2023. PMID: 38110114
216 results